NEW YORK—Zoetis shares declined after the Food and Drug Administration requested additional data on its canine osteoarthritis vaccine candidate, pushing the anticipated approval timeline back by at least six months and disappointing investors who expected a quicker launch for a key growth driver. ZTS fell 8 percent from recent highs, compared with a 2.4 percent drop in the Nasdaq.
The selloff overstates the long-term impact. Zoetis holds a dominant position in the companion animal health market, a segment growing at a consistent 7 percent compound annual rate. Its existing portfolio—including Apoquel for allergies and Convenia for infections—continues to deliver predictable revenue growth. The company reported $2.2 billion in first-quarter revenue, up 9 percent year-over-year.
The pullback creates a clear entry point for long-term investors. Zoetis has more than 15 products in late-stage development across multiple species and therapeutic areas. Cantor Fitzgerald reiterated its Overweight rating and $220 price target, citing the company's consistent innovation and market leadership—roughly 19 percent upside from recent levels.
The animal health sector benefits from durable, non-discretionary trends: rising global pet ownership and growing veterinary spending. As the largest pure-play animal health company, Zoetis is well-positioned to capture that secular growth, with diversified revenue streams and a strong balance sheet to absorb short-term regulatory setbacks.
Zoetis has a consistent record of working through regulatory processes and bringing products to market. Its global footprint and direct sales force support efficient distribution once approvals are secured. At current prices, investors are getting a high-quality growth franchise at a discount the fundamentals do not justify.
